Monoclonal Anti-CD38 and Anti-47 Interference and Strategies in Compatibility Testing

doi:10.3969/j.issn.1671-2587.2023.04.026

JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2023, Vol. 25 ›› Issue (4): 559-563.DOI: 10.3969/j.issn.1671-2587.2023.04.026

Previous Articles Next Articles

Monoclonal Anti-CD38 and Anti-47 Interference and Strategies in Compatibility Testing

WANG Fei, CHEN Yaozhen, HU Xingbin, et al

Xi'an Medical University, Xi'an 710032

Received:2023-06-02 Online:2023-08-20 Published:2023-09-18

Abstract

Abstract: More recently, novel monoclonal antibodies targeting immune checkpoints related signaling pathways have shown promise in the field of cancer immunotherapy. Hu5F9-G4, IBI188, and Daratumumab, designed specifically to target CD47 and CD38, have demonstrated clinical efficacy in patients with lymphoma, multiple myeloma, and other malignancies. Because CD38 and CD47 molecules are expressed not only on tumor cells, but also on red blood cells, anti-CD38 or anti-CD47 antibodies are specifically bound to red blood cells in the blood of patients treated with anti-CD38 and anti-CD47 monoclonal drugs. This leads to false positives in compatibility testing, such as blood typing, cross-matching and irregular antibody screening etc., which poses a risk to transfusion safety. In this paper, the interference problems of anti-CD38 and anti-CD47 on blood transfusion compatibility testing and the existing elimination strategies are described to provide reference for minimizing the impact of anti-CD38 and anti-CD47 on blood transfusion safety.

Key words: Monoclonal antibody drugs, CD38, CD47, Compatibility testing

CLC Number:

R457

WANG Fei, CHEN Yaozhen, HU Xingbin, et al. Monoclonal Anti-CD38 and Anti-47 Interference and Strategies in Compatibility Testing[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(4): 559-563.

References

[1] TORRE L A,SIEGEL R L,WARD E M,et al.Global cancer incidence and mortality rates and trends—an update[J].Cancer Epidemiol Biomarkers Prev,2016,25(1):16-27.
[2] ZENG Y.Advances in mechanism and treatment strategy of cancer[J].Cell Mol Biol,2018,64(6):1-3.
[3] AHN R,CUI Y F,WHITE F M.Antigen discovery for the development of cancer immunotherapy[J].Semin Immunol,2023,66:101733.
[4] ZHONG L,LI Y S,XIONG L,et al.Small molecules in targeted cancer therapy:advances,challenges,and future perspectives[J].Signal Transduct Target Ther,2021,6(1):201.
[5] MULLARD A.FDA approves 100th monoclonal antibody product[J].Nat Rev Drug Discov,2021,20(7):491-495.
[6] 李转丽,石亚军,白海.达雷妥尤单抗在血液系统疾病治疗中的应用及其耐药机制的研究进展[J].现代肿瘤医学,2023,31(1):192-196.
[7] 贺正希,刘惺,周艳宏.CD38在临床肿瘤治疗中作用的研究进展[J].中南大学学报(医学版),2022,47(7):952-959.
[8] 陈楚翘. CD38缺失对小鼠巨噬细胞TLR2介导的炎症反应的影响及机制研究[D].南昌:南昌大学,2015.
[9] 李荣臻. 平滑肌细胞特异性敲除CD38基因对AngⅡ诱导小鼠血压升高及血管重塑的影响及其机制[D].南昌:南昌大学,2022.
[10] 张莉,蒋丽,莫梅珍.CD38和CD138在子宫内膜异位症患者中的表达及意义[J].中国优生与遗传杂志,2022,30(12):2144-2149.
[11] VAN DE DONK N W C J,RICHARDSON P G,MALAVASI F.CD38 antibodies in multiple myeloma:back to the future[J].Blood,2018,131(1):13-29.
[12] VAN DE DONK N W C J,USMANI S Z.CD38 antibodies in multiple myeloma:mechanisms of action and modes of resistance[J].Front Immunol,2018,9:2134.
[13] VAN DE DONK N W C J.Immunomodulatory effects of CD38-targeting antibodies[J].Immunol Lett,2018,199:16-22.
[14] CHINI E N,CHINI C C S,ESPINDOLA NETTO J M,et al.The pharmacology of CD38/NADase:an emerging target in cancer and diseases of aging[J].Trends Pharmacol Sci,2018,39(4):424-436.
[15] TZOUNAKAS V L,SEGHATCHIAN J,GROUZI E,et al.Red blood cell transfusion in surgical cancer patients:targets,risks,mechanistic understanding and further therapeutic opportunities[J].Transfus Apher Sci,2017,56(3):291-304.
[16] TORRES M E U,RODRÍGUEZ J N R,RAMOS J L S,et al.Transfusion in palliative cancer patients:a review of the literature[J].J Palliat Med,2014,17(1):88-104.
[17] LANCMAN G,ARINSBURG S,JHANG J,et al.Blood transfusion management for patients treated with anti-CD38 monoclonal antibodies[J].Front Immunol,2018,9:2616.
[18] CHAPUY C I,NICHOLSON R T,AGUAD M D,et al.Resolving the daratumumab interference with blood compatibility testing[J].Transfusion,2015,55(6 Pt 2):1545-1554.
[19] MCELLISTRIM C,KRAWCZYK J,O'DWYER M.New developments in the treatment of multiple myeloma-clinical utility of daratumumab[J].Biol,2017,11:31-43.
[20] 糜坚青,蔡晓红,王少元,等.CD38单克隆抗体对输血相容性检测干扰及其应对方案的专家共识[J].中国输血杂志,2021,34(4):327-334.
[21] NEDUMCHERIL M T,DESIMONE R A,RACINE-BRZOSTEK S E,et al.Overcoming drug interference in transfusion testing:a spotlight on daratumumab[J].J Blood Med,2021,12:327-336.
[22] SONG J A,FU R.Review:effects of anti-CD38 monoclonal antibodies on red blood cell transfusion and interventions[J].J Clin Lab Anal,2021,35(12): e23832.
[23] EHREND E,MANNS P,HARENKAMP S,et al.Preanalytic depletion of medicinal anti-CD38 antibody from patient plasma for immunohematology testing[J].Blood,2021,138(9):814-817.
[24] 李剑平,李娇,李晓丰.红细胞血型的免疫学检测与基因检测的现状和展望[J].诊断学理论与实践,2015,14(6):491-493.
[25] DE VOOGHT K M K,OOSTENDORP M,VAN SOLINGE W W.New MAb therapies in multiple myeloma[J].Curr Opin Hematol,2016,23(6):557-562.
[26] 刘志新,赵静雅,尹郸丹,等.排除抗-CD38单克隆抗体药物对抗人球蛋白检测干扰的试剂:CN112285361A[P].2021-01-29.
[27] ZHAO J Y,LIU Z X,YIN D D,et al.TCEP-HCl can resolve the daratumumab interference[J].Blood&Genomics,2021,5(2):121-127.
[28] 沈一凡,吴徳沛,徐杨.靶向CD47治疗髓系肿瘤的相关进展[J].临床血液学杂志,2022,35(9):689-693.
[29] JIANG Z X,SUN H,YU J F,et al.Targeting CD47 for cancer immunotherapy[J].J Hematol Oncol,2021,14(1):180.
[30] JIA X,YAN B J,TIAN X Q,et al.CD47/SIRPα pathway mediates cancer immune escape and immunotherapy[J].Int J Biol Sci,2021,17(13):3281-3287.
[31] ZHANG W T,HUANG Q H,XIAO W W,et al.Advances in anti-tumor treatments targeting the CD47/SIRPα axis[J].Front Immunol,2020,11:18.
[32] BRIERLEY C K,STAVES J,ROBERTS C,et al.The effects of monoclonal anti-CD47 on RBCs,compatibility testing,and transfusion requirements in refractory acute myeloid leukemia[J].Transfusion,2019,59(7):2248-2254.
[33] ZHOU F Y,FENG B,YU H J,et al.Tumor microenvironment-activatable prodrug vesicles for nanoenabled cancer chemoimmunotherapy combining immunogenic cell death induction and CD47 blockade[J].Adv Mater,2019,31(14):e1805888.
[34] 陈洁,胡兴斌,陈要臻,等.单克隆抗-CD47干扰输血前检测:国内外临床试验案例分析[J].中国输血杂志,2021,34(11):1215-1218.
[35] DU C H,SUI W J,HUANG H T,et al.Effect of clinical application of anti-CD38 and anti-CD47 monoclonal antibodies on blood group detection and transfusion therapy and treatment[J].Leuk Res,2022,122:106953.
[36] VELLIQUETTE R W,AESCHLIMANN J,KIRKEGAARD J,et al.Monoclonal anti-CD47 interference in red cell and platelet testing[J].Transfusion,2019,59(2):730-737.
[37] 吕依扬,孔文兵,陈晓钢,等.抗-CD47单抗对输血相容性检测的干扰及处理[J].中国输血杂志,2023,36(3):238-241.
[38] JONES A D,MOAYERI M,NAMBIAR A.Impact of new myeloma agents on the transfusion laboratory[J].Pathology,2021,53(3):427-437.
[39] FENG R D,ZHAO H,XU J G,et al.CD47:the next checkpoint target for cancer immunotherapy[J].Crit Rev Oncol Hematol,2020,152:103014.
[40] CHEN Y C,SHI W,SHI J J,et al.Progress of CD47 immune checkpoint blockade agents in anticancer therapy:a hematotoxic perspective[J].J Cancer Res Clin Oncol,2022,148(1):1-14.
[41] MEI Z,WOOL G D.Impact of novel monoclonal antibody therapeutics on blood bank pretransfusion testing[J].Hematol Oncol Clin North Am,2019,33(5):797-811.
[42] BRANCH D R.Immunotherapy:the good,the bad,the ugly,and the really ugly[J].Transfusion,2019,59(2):437-440.

Monoclonal Anti-CD38 and Anti-47 Interference and Strategies in Compatibility Testing

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 2

Recommended Articles

Metrics

Comments

About

Author

Journal

Access Statistics

Contact

[1]	SHAO Lin-nan, ZHANG Shu-ting, WANG Ni, et al. Study for the Removal of CD38 Antigen on the Surface of Red Blood Cells by Three Different Reagents [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2021, 23(1): 65-67.
[2]	LI Wei-Chao, CHENG Dao-Sheng. The Blood Matching Strategy of CD38 Monoclonal Antibody in Treating Multiple coli Myeloma [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2020, 22(6): 624-626.